Related Experiment Video
Updated: Jan 1, 2026
Simultaneous Measurement of Superoxide/Hydrogen Peroxide and NADH Production by Flavin-containing Mitochondrial Dehydrogenases
Published on: February 24, 2018
Isoform-selective NADPH oxidase inhibitor panel for pharmacological target validation
Vu Thao-Vi Dao1, Mahmoud H Elbatreek2, Sebastian Altenhöfer3
1Department for Pharmacology and Personalised Medicine, FHML, Maastricht University, Maastricht, the Netherlands; Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt, Germany.
Targeting specific sources of reactive oxygen species (ROS), like NADPH oxidases (NOX), offers a promising therapeutic strategy. This study demonstrates achievable, though not yet perfect, isoform selectivity with NOX inhibitors, paving the way for targeted treatments.
Area of Science:
- Biochemistry and Molecular Biology
- Pharmacology and Therapeutics
- Cellular Signaling and Oxidative Stress
Background:
- Dysfunctional reactive oxygen species (ROS) signaling is implicated in various disease mechanisms.
- Broad antioxidant therapies targeting ROS have shown limited clinical benefit.
- Enzymatic sources of ROS, particularly NADPH oxidases (NOX), are emerging as key therapeutic targets.
Purpose of the Study:
- To investigate the potential for isoform-selective pharmacological modulation of NADPH oxidase (NOX) enzymes.
- To assess the specificity of existing NOX inhibitors across different NOX isoforms.
- To establish a proof-of-principle for pharmacological target validation in a human disease model.
Main Methods:
- Evaluation of five NOX inhibitors for their inhibitory concentration (IC50) against different NOX isoforms.
- Assessment of potential assay artifacts and non-specific antioxidant effects.
- Application of an inhibitor panel at IC50 concentrations in a human ischemic blood-brain barrier hyperpermeability model.
Main Results:
- Achieved varying degrees of isoform selectivity for NOX inhibitors, with specific compounds showing potent inhibition of NOX1, NOX2, NOX4, and NOX5.
- Identified limitations in individual compound specificity and potential confounding factors like assay artifacts.
- Demonstrated the feasibility of pharmacological target validation for NOX isoforms in a human ex vivo model.
Conclusions:
- Pharmacological modulation of specific NOX isoforms represents a viable therapeutic strategy, overcoming limitations of non-selective ROS scavenging.
- While current NOX inhibitors show promise for isoform selectivity, further lead optimization is necessary for enhanced specificity.
- The findings support continued development of isoform-selective NOX inhibitors for various disease indications.
